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Summary
Background Cannabis use following the onset of first-episode psychosis has been linked to both increased risk of 
relapse and non-adherence with antipsychotic medication. Whether poor outcome associated with cannabis use is 
mediated through an adverse effect of cannabis on medication adherence is unclear.
Methods In a prospective analysis of data acquired from four different adult inpatient and outpatient units of the 
South London and Maudsley Mental Health National Health Service Foundation Trust in London, UK, 245 patients 
were followed up for 2 years from the onset of first-episode psychosis. Cannabis use after onset of psychosis was 
assessed by self-reports in face-to-face follow-up interviews. Relapse data were collected from clinical notes using the 
WHO Life Chart Schedule. This measure was also used to assess medication adherence on the basis of both face-to-
face interviews and clinical notes. Patients were included if they had a diagnosis of first-episode non-organic or 
affective psychosis according to ICD-10 criteria, and were aged between 18 and 65 years when referred to local 
psychiatric services. We used structural equation modelling analysis to estimate whether medication adherence partly 
mediated the effects of continued cannabis use on risk of relapse. The primary outcome variable was relapse, defined 
as admission to a psychiatric inpatient unit after exacerbation of symptoms within 2 years of first presentation to 
psychiatric services. Information on cannabis use over the first 2 years after onset of psychosis was investigated as a 
predictor variable for relapse. Medication adherence was assessed as a mediator variable on the basis of clinical 
records and self-report data. Study researchers (TS, NP, EK, and EF) rated the adherence.
Findings 397 patients who presented with their first episode of psychosis between April 12, 2002, and July 26, 2013 had 
a follow-up assessment until September, 2015. Of the 397 patients approached for followed up, 133 refused to take part 
in this study and 19 could not be included because of missing data. 91 (37%) of 245 patients with first-episode psychosis 
had a relapse over the 2 years of follow-up. Continued cannabis use predicted poor outcome, including risk of relapse, 
number of relapses, length of relapse, and care intensity at follow-up. In controlled structural equation modelling 
analyses, medication adherence partly mediated the effect of continued cannabis use on outcome, including risk of 
relapse (proportion mediated=26%, βindirect effects=0·08, 95% CI 0·004 to 0·16), number of relapses (36%, βindirect effects=0·07, 
0·003 to 0·14), time until relapse (28%, βindirect effects=–0·26, –0·53 to 0·001) and care intensity (20%, βindirect effects=0·06, 
0·004 to 0·11) but not length of relapse (6%, βindirect effects=0·03, –0·03 to 0·09). The adjusted models explained moderate 
amounts of variance for outcomes defined as risk of relapse (R²=0·25), number of relapses (R²=0·21), length of relapse 
(R²=0·07), time until relapse (R²=0·08), and care intensity index (R²=0·15).
Interpretation Between 20% and 36% of the adverse effects of continued cannabis use on outcome in psychosis might 
be mediated through the effects of cannabis use on medication adherence. Interventions directed at medication 
adherence could partly help mitigate the harm from cannabis use in psychosis.
Funding This study is funded by the National Institute of Health Research (NIHR) Clinician Scientist award.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Risk of relapse after the first episode of psychosis is 
high,1 constituting a substantial burden for health-care 
systems around the world,2,3 and this relapse affects both 
individuals and society at large.4 In particular, relapse 
during the first few years after onset of the psychotic 
episode is an important determinant for long-term 
clinical and functional outcome.5 Hence, prevention of 
relapse is a crucial treatment target, which in turn 
underscores the importance of identification of 
modifiable risk factors that could influence relapse. 
Although the multifactorial nature of relapse is well 
known,6 two consistently identified modifiable risk 
factors influencing relapse are continued cannabis use 
following onset of psychosis7–9 and medication non-
adherence,10,11 both of which are unlikely to be the result 
of confounding or reverse causation.12 Despite the fact 
that the prevalence of post-onset cannabis use13 and 
medication non-adherence12 in patients with psychosis is 
high, understanding of the effects of this remains poor.
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There is poor understanding about how risk factors such 
as cannabis use might affect outcome in psychosis. 
Previous studies9,14 have shown that the effect of cannabis 
use on risk of relapse was reduced when medication 
adherence was controlled for, suggesting that cannabis 
use could adversely affect psychosis outcome partly by 
influencing adherence to antipsychotic medication. This 
is consistent with independent evidence from a meta-
analysis15 suggesting a significant effect of continued 
cannabis use on adherence to antipsychotic medication 
in patients with psychosis (p<0·0001), which was also 
confirmed by the five studies9,12,16–18 that investigated this 
issue subsequently. However, no study to date has 
systematically investigated to what extent the association 
between cannabis use and relapse of psychosis is 
mediated by non-adherence with prescribed psychotropic 
medication. By elucidating the mechanistic pathway 
from cannabis use to psychosis relapse in first episode of 
psychosis in terms of potential mediational processes, 
we might be able to help identify alternative targets for 
intervention that could help mitigate the harm from 
cannabis use. Hence, in the present study, we aimed to 
explore whether some of the adverse effects of continued 
cannabis use on risk of relapse can be explained by its 
association with medication adherence; whether the 
association between continued cannabis use and risk of 
relapse is only partly, but not fully, mediated by 
medication adherence; and whether mediation effects 
are also present for other relapse-related outcomes, 
including number of relapses, length of relapse, time 
until relapse occurs, and intensity of care (eg, low-
intensity outpatient care or high-intensity involuntary 
admission under section).
Methods
Study design and participants
All patients included in this prospective analysis were 
recruited from four different adult inpatient and 
outpatient units of the South London and Maudsley 
(SLAM) Mental Health National Health Service (NHS) 
Foundation Trust in Lambeth, Southwark, Lewisham, 
and Croydon as part of a follow-up study aiming to 
investigate the role of cannabis use within the first 
2 years after onset of psychosis. Patients had a clinical 
diagnosis of first-episode non-organic (non-affective 
[ICD-10 codes F20–F29] or affective [F30–F33]) psychosis19 
and were aged between 18 and 65 years when referred to 
local psychiatric services in south London, UK. We have 
previously reported on methods for assessment of 
patients and data acquisition.9,12 This study was granted 
Research in context
Evidence before this study
We searched MEDLINE databases from inception to 
April 12, 2017, using a combination of search terms for 
describing diagnosis (psychosis: “psychosis”, “psychot*”, 
“schizophren*”, “schizoaff*”), exposure (cannabis use: 
“cannabi*”), and outcome of interest (medication adherence: 
“adheren*”, “complian*”), which retrieved 2092 articles, 
of which 20 were selected according to the following three 
criteria: (1) investigated the relationship between cannabis use 
and medication adherence; (2) the majority of the sample were 
taking antipsychotic medication; (3) participants were 
diagnosed with schizophrenia or any psychotic disorder using 
standardised criteria. We have previously summarised 15 of 
these studies (those published before April 27, 2015) as part of 
a meta-analysis, and these results showed that continued 
cannabis use increased the risk for non-adherence to 
antipsychotic medications. Results of the five additional 
studies that had been published since the original literature 
search were consistent with the results of our previous 
meta-analysis and confirmed that cannabis users were less 
likely to adhere to their prescribed medication than people 
who did not use cannabis. Of all relevant studies, only 
one investigated whether the effect of cannabis use on 
medication adherence mediated its effects on outcome in 
psychosis. They used data obtained from clinical records to 
report that poor medication adherence mediated the adverse 
effect of cannabis use on non-remission at 1 year in patients 
with psychosis. However, not all patients continue using 
cannabis following the onset of psychosis and a substantial 
proportion stop using the drug, a factor that was not 
accounted for by Colizzi and colleagues. Hence, whether 
non-adherence to antipsychotics truly mediates the effect of 
continued cannabis use following the onset of psychosis and 
the extent of this effect is unclear.
Added value of this study
The present study extends current evidence on cannabis use 
being associated with increased risk of relapse in psychosis by 
investigating how it might be exerting this effect, focusing 
particularly on adherence to antipsychotic medication. The 
study benefits from data obtained in follow-up assessments of 
a large sample of patients with first-episode psychosis, which 
allowed a more detailed assessment of cannabis use profiles 
and pattern of medication adherence and the consideration of 
potential confounders. We explored consistency of effects by 
using different outcome measures of relapse, including risk or 
number of relapses, length of relapse, time until relapse, 
and severity of relapse.
Implications of all the available evidence
Collectively, the results of the present study and previous 
evidence indicate that relapse of psychosis associated with 
continued cannabis use might be partly mediated through 
non-adherence with prescribed medication. Hence, future 
investigations should test whether interventions aimed at 
improving medication adherence could partly help mitigate 
the adverse effects of cannabis use on outcome in psychosis.
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ethical approval by South London & Maudsley NHS 
Foundation Trust and the Institute of Psychiatry Local 
Research Ethics Committee. All patients included in the 
study gave written informed consent.
Outcomes
We obtained information regarding use of services, 
including number, duration, and legal status of inpatient 
admissions and referral to crisis intervention team or 
standard treatment by a community mental health team 
from electronic patient records, using the WHO Life 
Chart Schedule.20 Age of onset of psychosis was defined 
as the age on the date of referral to local psychiatric 
services for a first episode of psychosis. Our main 
outcome variable of interest was risk of relapse, which 
we defined as admission to a psychiatric inpatient unit 
owing to exacerbation of psychotic symptoms within 
2 years following first presentation to psychiatric services. 
This outcome has been linked to both cannabis use and 
medication adherence in those with first episode of 
psychosis.9,12 Other relapse-related outcome measures 
included the number of relapses; the length of relapse; 
the time to first relapse; the care intensity at follow-up 
(rating each patient’s intensity of service use over the 
first 2 years following illness onset; appendix).
We assessed cannabis use as a predictor variable using 
a modified version of the Cannabis Experience 
Questionnaire (CEQmv),9 obtaining data on cannabis use 
over the first 2 years following onset of psychosis. In line 
with previous work,12 cannabis users were classified on 
the basis of their pattern of continuation of use after 
onset, categorising them into different categories (0=not 
a cannabis user [no use or use only once or twice after 
onset], 1=intermittent cannabis user [used cannabis 
more than twice but not every month within the 2-year 
period], or 2=continued cannabis user [used cannabis 
every month throughout all of the 24 follow-up months]). 
The cannabis use variable was coded as ordered 
categorical.
We assessed medication adherence as a mediator 
variable within the first 2 years after onset by use of the 
Life Chart Schedule.20 Similar to previous reports,12 the 
variable was classified on the basis of information on 
prescription and ratings of adherence (3=non-adherence 
[67–100% of the time non-compliant]; 2=irregular 
adherence [34–66% of the time non-compliant]; 1=good 
adherence [0–33% of the time non-compliant], or 
0=medication not prescribed within the 2 years following 
the onset of illness).
Other factors that have previously been reported to be 
associated with relapse were also included in the model 
as covariates, including other illicit drug use,21,22 ethnic 
origin,4,9 and care intensity at psychosis onset as an index 
of illness severity when presenting with the first episode.9,23 
As done in previous studies,12 data from the CEQmv and 
WHO Life Chart Schedule20 were used to derive the 
following variables. Other drug use was defined as the 
use of illicit drugs other than cannabis within the first 
2 years after onset. This variable was coded as a categorical 
variable (2=regular use [six times or more]; 1=experimental 
use [less than six times]; 0=no use). Care intensities at 
onset and follow-up were computed by rating each 
patient’s intensity of service use at onset or follow-up, 
respectively.
Statistical analysis
We created structural equation modelling analyses 
represented by path diagrams to measure the mediating 
effect of medication adherence on the association 
between cannabis use and relapse (appendix). We 
estimated standardised direct, indirect, and total effects 
using R and its package Lavaan.24 We estimated bias-
corrected 95% CIs using 1000 bootstrap samples. The 
initial simple models estimated path coefficients for 
continued cannabis use as a predictor for medication 
adherence, continued cannabis use as a predictor for 
relapse and relapse-related outcomes, and medication 
adherence as a predictor for relapse and relapse-related 
outcomes. As part of the mediation analysis, a direct 
effect refers to the standardised path coefficient 
between continued cannabis use and risk of relapse 
(path C), and an indirect effect to the product of the 
standardised path coefficient between path A and 
path B (figure). The total effect of cannabis use on risk 
of relapse is the sum of direct and indirect effects. 
Mediation occurred if the indirect effect was significant. 
Structural equations for each endogenous variable in 
the pathway model were adjusted for the potential 
confounding effects of ethnic origin, other illicit drug 
use, and illness severity at onset as indexed by the level 
of care intensity at onset. We aimed to further explore 
an alternative reverse mediation model to compare 
with the proposed mediation model. In this reverse 
mediation model for risk of relapse and related 
outcomes, continued cannabis use was treated as the 
mediator variable and medication adherence as the 
independent variable. It is suggested that the predicted 
mediation model would be more convincing if the 
reverse model identifies only non-significant indirect 
paths.25
See Online for appendix
Figure: Path model—medication adherence as a mediator of the association between continued cannabis use 
and relapse
Conceptualised pathways between continuation of cannabis use and risk of relapse, with the total effects 
transmitting both directly (solid line—C), and indirectly (dashed lines—A and B) via medication adherence.
Other illicit dug use, ethnic origin,
onset care intensity
Medication adherence
Risk of relapseContinuation of cannabis use
A
C
B
Direct/unexplained effect
Indirect/mediated effects
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Role of the funding source
The views expressed are those of the authors and not 
necessarily those of the NHS, the National Institute of 
Health Research (NIHR), or the Department of Health. 
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. All authors have 
approved the final version of the paper.
Results
397 patients who presented with their first episode of 
psychosis between April 12, 2002, and July 26, 2013, were 
approached for follow-up and had an assessment up until 
September, 2015. Of the 397 patients, 133 refused to take 
part in this study and 19 could not be included because of 
missing data. We followed up 245 patients with first-
episode psychosis for 2 years from onset. 91 (37%) of 
245 patients with first-episode psychosis had a relapse 
over the 2 years after onset of psychosis (table 1). Most 
patients reported regular (45%) or irregular (42%) 
adherence with the pre scribed medication, whereas 
only a small subset of patients (14%) reported non-
compliance. Although most patients were classified as 
not cannabis users following the onset of psychosis 
(146 [60%], including 98 [40%] who were never a regular 
user, and 48 [20%] who had been former regular users), 
the remaining patients were classified either as 
intermittent cannabis users (36 patients [15%]) or 
continued cannabis users (63 patients [26%]). 
Comparing those who relapsed to those who did not 
relapse revealed that the relapsing patient group was 
more likely to be classified as continued cannabis users 
Total (n=245) Non-relapsing (n=154) Relapsing (n=91) p value* 95% CI†
Gender, male 147 (60%) 94 (64%) 53 (36%) 0·77 –0·16 to 0·64
Ethnic origin, non-white 161 (66%) 92 (57%) 69 (43%) 0·015 0·034 to 0·30
Age of onset 28·20 (8·11) 28·43 (8·00) 27·81 (8·33) 0·34 –0·89 to 2·53
Onset diagnosis, non-affective 202 (82%) 125 (62%) 77 (38%) 0·61 –0·22 to 0·11
Care intensity at onset‡ ·· ·· ·· 0·015 ··
Referral to community team only 40 (16%) 25 (63%) 15 (38%) ·· ··
Required contact with crisis team 18 (<1%) 5 (28%) 13 (72%) 0·030 0·05 to 0·64
Required hospital admission (non-compulsory) 74 (30%) 50 (68%) 24 (32%) 0·74 –0·26 to 0·15
Required hospital admission (compulsory) 113 (46%) 74 (66%) 39 (35%) 0·88 –0·22 to 0·16
Other drug use, regular use 26 (11%) 12 (46%) 14 (54%) 0·099 –0·04 to 0·41
Cannabis use‡ ·· ·· ·· 0·0034 ··
Never (regular) user 98 (40%) 69 (70%) 29 (30%) ·· ··
Former (regular) user 48 (20%) 35 (73%) 13 (27%) 0·90 –0·20 to 0·17
Intermittent user 36 (15%) 22 (61%) 14 (39%) 0·42 –0·11to 0·30
Continued user 63 (26%) 28 (44%) 35 (56%) 0·0018 0·09 to 0·43
Medication adherence‡ ·· ·· ·· <0·0001 ··
Regular adherence 109 (45%) 86 (79%) 23 (21%) ·· ··
Irregular adherence 102 (42%) 54 (53%) 48 (47%) 0·0001 0·13 to 0·39
Non-adherence 34 (14%) 14 (41%) 20 (59%) <0·0001 0·18 to 0·58
Data are n (%) or mean (SD). *χ² test for independence to compare distributions and Mann-Whitney U (two-sided) test to compare means between the groups (non-relapsing 
vs relapsing). †95% CI to estimate the difference between two proportions and two means. ‡χ² test for independence and 95% CI estimate of the difference between 
two proportions for care intensity at onset (reference group=referral to community team only), cannabis use (reference group=never [regular] user), and medication 
adherence (reference group=regular adherence).
Table 1: Sample characteristics
Cannabis (n=245) Medication adherence (n=245)
β (SE) 95%CI p value R² β (SE) 95%CI p value R²
Risk of relapse 0·35 (0·10) 0·16 to 0·53 0·0003 0·081 0·56 (0·12) 0·33 to 0·80 <0·0001 0·14
Number of relapses 0·28 (0·09) 0·10 to 0·46 0·0019 0·055 0·51 (0·11) 0·28 to 0·73 <0·0001 0·11
Length of relapse 0·53 (0·17) 0·20 to 0·85 0·0016 0·039 0·38 (0·21) –0·02 to 0·79 0·064 0·01
Time until relapse –1·11 (0·50) –2·08 to –0·14 0·024 0·020 –2·33 (0·60) –3·49 to –1·16) <0·0001 0·06
Care intensity index 0·32 (0·09) 0·15 to 0·49 0·0002 0·070 0·52 (0·11) 0·31 to 0·74 <0·0001 0·12
Significant association of cannabis use as a predictor for medication non-adherence (β=0·31, SE=0·11, 95% CI 0·093 to 0·53, p=0·0052, R2=0·046).
Table 2: Path estimates for cannabis use and medication adherence as predictors for relapse outcome
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(p=0·0018, 95% CI 0·09–0·43) and as non-adherent 
(p<0·0001, 0·18–0·58) or irregularly adherent 
(p=0·0001, 0·13–0·39) with the prescribed medication. 
With regard to the other demographic and clinical 
characteristics, the relapsing group was more likely to 
be of non-white ethnic origin (p=0·015, 0·034 to 0·30) 
and appeared to have used other illicit drugs more 
regularly following the onset of first-episode psychosis 
(p=0·099, –0·04 to 0·41).
The simple path models identified the following 
associations between the variables of interest (table 2): 
a significant positive association between the level of 
cannabis use continuation and the risk of relapse, 
number of relapses, length of relapse, care intensity 
index at follow-up, and time until a relapse occurred. The 
proposed mediator, medication adherence, was linked to 
both the cannabis use variable and the relapse outcome, 
including risk of relapse, number of relapses, time until 
a relapse occurred, and care intensity index, but not 
length of relapse, suggesting that poor adherence was 
predictive of worse outcome in the 2 years following 
onset of psychosis.
Adjusting all models for ethnic origin, other illicit 
drug use, and intensity of care at onset, the structural 
equation modelling analyses are reported in table 3. 
They revealed that the association between continued 
cannabis use and risk of relapse was mediated (26·4% 
as the proportion of total effect mediated) by medication 
adherence (direct effect: β=0·22, 95% CI 0·03–0·42, 
p=0·027; indirect effect: β=0·08, 0·004–0·16, p=0·040), 
suggesting a partial but not full mediation by 
medication adherence of the effect of cannabis use on 
risk of relapse. For risk of relapse, the model explained 
25% of the variance, so 75% is not explained by this 
model. Explained variance is the extent to which a 
statistical model accounts for the variation in the 
dependent variable. The direct effect is the path 
between continued cannabis use and risk of relapse, 
and the indirect effect is the product of the path 
coefficients of the effect of cannabis use and medication 
adherence and the effect of medication adherence on 
risk of relapse. A similar effect was seen for care 
intensity index at follow-up, for which medication 
adherence mediated 19·7% of the effect of continued 
cannabis use, again implicating partial mediation 
based on significant indirect and direct effects. A larger 
proportion of the effect of continued cannabis use on 
the number of relapses of psychosis and time until 
relapse was mediated by medication adherence. No 
significant mediation effect was present for length of 
relapse. The adjusted models explained moderate 
amounts of variance for outcomes defined as risk of 
relapse (R²=0·23), number of relapses (R²=0·21), 
length of relapse (R²=0·07), time until relapse 
(R²=0·08), and care intensity index (R²=0·15).
Testing of the alternative models with the cannabis use 
variable as the proposed mediator indicated that 
continued cannabis use did not mediate the association 
between medication non-adherence and the different 
relapse outcomes after controlling for covariates. We 
tested two different theoretical models, which were a 
mediation model that tested whether medication 
adherence mediated the effect of cannabis use on 
outcome and a reverse arrow model that tested whether 
cannabis use mediated the effect of medication 
adherence on outcome.25 Studies have used this approach 
to evaluate which of the proposed mediators (medication 
adherence or cannabis use) is more valid.  In those 
models, medication adherence had a significant direct 
effect on risk of relapse (β=0·45, 95% CI 0·20–0·70, 
p=0·0004), number of relapses (β=0·42, 0·18–0·65, 
p=0·0005), care intensity index at follow-up (β=0·42, 
0·19–0·65, p=0·0003), and time until a relapse occurred 
(β=–2·00, –3·18 to –0·81, p=0·0010), indicating that 
cannabis use did not fully confound the effects of 
medication adherence on outcome. There were no 
indirect effects for risk of relapse, number of relapses, 
time until a relapse occurred, and care intensity index at 
follow-up, which further suggested that cannabis use did 
not mediate the effects of medication adherence on these 
relapse outcomes. For length of relapse, there were no 
indirect or direct effects for medication adherence.
Discussion
To the best of our knowledge, this is the first study that 
examines medication adherence as a mediator of the 
β (SE) p value 95% CI* R²
Risk of relapse ·· ·· ·· 0·25
Indirect effect 0·08 (0·04) 0·040 0·004 to 0·16 ··
Direct effect 0·22 (0·10) 0·027 0·03 to 0·42 ··
Proportion of total effect mediated (%) 26·4% ·· ·· ··
Number of relapses ·· ·· ·· 0·21
Indirect effect 0·07 (0·04) 0·040 0·003 to 0·14 ··
Direct effect 0·13 (0·10) 0·20 –0·07 to 0·34 ··
Proportion of total effect mediated (%) 35·5% ·· ·· ··
Length of relapse ·· ·· ·· 0·07
Indirect effect 0·03 (0·03) 0·35 –0·03 to 0·09 ··
Direct effect 0·40 (0·18) 0·024 0·05 to 0·75 ··
Proportion of total effect mediated (%) 6·4% ·· ·· ··
Time until relapse ·· ·· ·· 0·08
Indirect effect –0·26 (0·13) 0·051 –0·53 to 0·001 ··
Direct effect –0·67 (0·52) 0·20 –1·68 to 0·35 ··
Proportion of total effect mediated (%) 28·3% ·· ·· ··
Care-intensity index ·· ·· ·· 0·15
Indirect effect 0·06 (0·03) 0·035 0·004 to 0·11 ··
Direct effect 0·24 (0·09) 0·008 0·06 to 0·42 ··
Proportion of total effect mediated (%) 19·7% ·· ·· ··
Pathways for all endogenous variables were adjusted for other illicit drug use, ethnic origin, and onset care intensity. 
*Bias corrected and accelerated 95% CI 1000 bootstrap samples.
Table 3: Mediation of the effect of cannabis use on relapse outcome
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association between continued cannabis use following 
illness onset and relapse, as indexed by admission to 
hospital, in patients with first-episode psychosis. The 
adverse effects of continued cannabis use on risk of 
relapse were partly but not fully mediated by its 
association with non-adherence with prescribed 
antipsychotic medication. More specifically, medication 
non-adherence mediated the effect of continued 
cannabis use on risk of relapse (26%), number of 
relapses (36%), time until a relapse occurred (28%), and 
care intensity index at follow-up (20%). Medication non-
adherence did not mediate the effect of continued 
cannabis use on length of relapse of psychosis. Our 
results not only indicate that those patients who continue 
to use cannabis following onset of their psychotic illness 
are also more likely to not take medications prescribed 
for their psychosis but also that this effect can partly 
explain why patients with first-episode psychosis who 
continue to use cannabis often suffer from a relapsing 
form of the illness.7,26 We8,9 and others7 have shown that 
cannabis use, especially continued use after onset of 
psychosis, is associated with relapse of psychosis 
resulting in admission to hospital and that this effect is 
more likely than not to be a causal association.12 This is 
consistent with other evidence implicating worse 
outcomes in patients with first-episode psychosis who 
continued to use cannabis when compared with those 
who stop using the substance.27 Here, we extend this 
previous work to show that the adverse effect of 
continued cannabis use on outcome in early psychosis is 
partly mediated by an effect on adherence with 
medication treatment. These findings are consistent 
with studies that identified an association between 
cannabis use and medication adherence,8,9,15,28 as well as 
between medication adherence and increased risk of 
relapse of psychosis.10,11 We have reported8 that failure of 
treatment with antipsychotic medication as indexed by 
the number of unique antipsychotic prescriptions could 
partly mediate the adverse effect of cannabis use on 
subsequent risk of relapse in first-episode psychosis. 
Although a change of antipsychotic medication could 
reflect a clinical judgment of failed treatment, several 
separate considerations either alone or in combination 
could lead to such a judgment, including one of 
treatment resistance, poor tolerability, or non-adherence 
to a specific antipsychotic. Until now, it has not been 
known which of these factors might explain how 
cannabis use could increase the risk of relapse. Results 
from the present study clearly point toward a mediating 
influence of poor medication adherence. Whether 
treatment resistance or poor tolerability also mediate 
some of the effects of cannabis use on relapse of 
psychosis is yet to be tested. Furthermore, other factors, 
such as depressive symptoms29 or cognitive function30 
that were not systematically investigated in this study 
could also have influenced the association between 
cannabis use and risk of relapse.
Overall, our results suggest that although efforts 
should no doubt continue to develop more effective 
interventions to help patients with psychosis to reduce 
their cannabis use—eg, similar to those cannabis-
focused treatment programmes that are currently 
under assessment,31 another potential approach to 
mitigating the harm from cannabis use might lie in 
ensuring better adherence of patients to their 
prescribed medication. It is worth noting that despite 
the identified mediation effect, a considerable 
proportion of the variance in the risk of relapse and 
related outcomes remains unexplained, varying 
between 7% and 25% depending on the specific 
outcome. Future studies including much larger 
samples are needed to consider other risk factors of 
interest as well as more complex model pathways to 
address the issue of unexplained variance in relapse 
outcome. In this context, it should be pointed out that 
the identified associations could also be bidirectional. 
It is worth noting that as the present study was an 
observational study, temporal ambiguity between the 
mediator and predictor variable as well as unmeasured 
confounders could have biased our results. Never-
theless, to partly address this limitation of absence 
of experimental data, we compared the proposed 
mediation model with an alternative path model with 
reversed arrows (ie, by including cannabis use as a 
mediating factor instead of medication adherence) but 
the results were not supportive of alternative path 
models that included cannabis use as a mediator of the 
associations between medication adherence and 
relapse outcome (for path estimates see appendix). 
Although other limitations of this study might relate to 
the nature of the retrospective assessment of cannabis 
use and medication adherence, and the inclusion of a 
selective subset of inner city patients with first-episode 
psychosis who were at least 18 years old, those issues 
are unlikely to have affected the results (appendix). We 
did not consider those who started using cannabis after 
the onset of psychosis but had no history of premorbid 
regular use as a separate group, since only 
three participants belonged to this category. How 
continued cannabis use might have resulted in poor 
adherence to medications in psychosis patients is 
unclear. Although it is possible that increased severity 
of psychosis,7 and consequently, impaired insight or 
memory32 as a result of continued cannabis use might 
explain poor adherence, this possibility was not 
investigated in the present study and warrants 
investigation in the future.
Our results suggest that up to a third of the adverse 
effect of cannabis use on outcome in first-episode 
psychosis could be mediated through its effect on 
medication adherence, suggesting that interventions 
aimed at improving medication adherence might partly 
help mitigate the adverse effects of cannabis use on 
outcome in psychosis.
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